Arena Rises on Lorcaserin FDA Briefing Docs Ahead of EMDAC
Briefing documents released in advance of Thursday's meeting of the FDA's Endocrinological and Metabolic Drugs Advisory Committee (EMDAC) suggested Arena Pharmaceuticals Inc. may have allayed many of the agency's concerns about the safety of its weight loss drug Lorqess (lorcaserin).
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter